Equities research analysts at StockNews.com assumed coverage on shares of China Pharma (NYSE:CPHI – Get Free Report) in a report issued on Tuesday. The brokerage set a “hold” rating on the stock.
China Pharma Price Performance
CPHI opened at $0.26 on Tuesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.89 and a quick ratio of 0.25. The company’s 50 day simple moving average is $0.28 and its two-hundred day simple moving average is $0.37. China Pharma has a 1-year low of $0.24 and a 1-year high of $1.95.
China Pharma (NYSE:CPHI – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.07) earnings per share for the quarter. China Pharma had a negative return on equity of 54.31% and a negative net margin of 55.42%. The business had revenue of $1.37 million during the quarter.
About China Pharma
China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Read More
- Five stocks we like better than China Pharma
- 3 Stocks to Consider Buying in October
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- Stock Analyst Ratings and Canadian Analyst Ratings
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- How to invest in marijuana stocks in 7 steps
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
